💊 Lupin to launch COPD generic in the US; Bangladesh to set up its first vaccine-making facility; The WHO says El Nino will bring disease
#368 | Pathbreaking moment for organ transplantation; Making fuel with atmospheric CO2; Mpox continues to rage in Africa
Hello, and welcome back to The Kable once again. It has been a hot minute since we've had a light issue of The Kable for you, but light it is today.
Continuing its perennial spree of research collabs, the Seoul-based International Vaccine Institute has inked a new agreement with Seoul National University to work together on (surprise) vaccine R&D.
India's Lupin has got the thumbs up from the US FDA for its generic version of Boehringer Ingelheim's blockbuster COPD treatment Spiriva.
The Pfizer and GSK RSV shots for older adults have got the thumbs up from the US CDC's advisors.
The Indian drugmaker implicated in the toxic syrups case in Liberia says it is impossible its syrup is toxic.
Mpox may no longer be an emergency for the WHO and for the countries that experienced it for the first time last year and promptly secured vaccine stockpiles. However, in Africa, where it is endemic, mpox continues to rage and ravage. Vaccines? What are vaccines?
A new study says lack of registration is limiting access to essential medicines in Kenya, Tanzania and Uganda.
And finally, in the most excellent news of the day, Bangladesh is all set to establish its first-ever vaccine manufacturing facility.